Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR (BIG-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02416388
Recruitment Status : Recruiting
First Posted : April 15, 2015
Last Update Posted : October 20, 2020
Sponsor:
Information provided by (Responsible Party):
University Hospital, Angers

Brief Summary:
This open label, multicenter phase II/III study with multiple randomization phases at differents stages of AML treatment (induction, consolidation and HSCT where applicable) is designed to improve OS in younger (18 to 60 year-old) patients, with AML risk-adapted patient strategies. Within the intermediate risk AML group, optimal GvHD prophylaxis following allogeneic SCT in first CR, after either myeloablative (MAC) or reduced intensity (RIC) conditioning, will also be evaluated. With an adaptative design, this clinical trial could test up to 3 novel AML agents of interest.

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia (AML) Drug: Idarubicin Drug: Daunorubicin Drug: HD Cytarabine Drug: Cyclosporine Drug: Methotrexate Drug: Mycophenolic acid (MPA) Drug: vosaroxin Drug: ID cytarabine Drug: Dexamethasone Drug: Venetoclax Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 3100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II/III Randomized Study to Improve Overall Survival in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus Mycophenolate Mofetil Prophylaxis of Graft Versus Host Disease in Allografted Patients in First CR : a Backbone InterGroup-1 Trial
Study Start Date : January 2015
Estimated Primary Completion Date : June 2024


Arm Intervention/treatment
Experimental: R1-IDA
Idarubicin
Drug: Idarubicin

Induction chemotherapy :

Idarubicin 9mg/m² /day, from D1 to D5 (IV, 30min)

+ cytarabine 200mg/m²/day from D1 to D7 (IV 24 h)

Bone marrow aspirate on D15 : if medullary blasts rate < 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L).


Active Comparator: R1-DAUNO
Daunorubicin
Drug: Daunorubicin

Induction chemotherapy :

Daunorubicin 90mg/m²/day, from D1 to D3 (IV, 30min)

+ cytarabine 200mg/m² /day from D1 to D7 (IV 24 h)

Bone marrow aspirate on D15 : if medullary blasts rate < 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L).


Active Comparator: R2-HDAC
High dose cytarabine
Drug: HD Cytarabine

Consolidation chemotherapy course (s) :

-High dose cytarabine: 3g/m² /12h on D1, D3 and D5

For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)

Up to 3 consolidation courses, depending on the patient AML risk group


Experimental: R2-IDAC
Intermediate dose cytarabine
Drug: ID cytarabine

Consolidation chemotherapy course (s) :

-Intermediate dose cytarabine: 1.5g/m² /12h on D1, D3 and D5

For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)

Up to 3 consolidation courses, depending on the patient AML risk group


Active Comparator: R3-MAC-MTX
Methotrexate and mycophenolic acid
Drug: Methotrexate

GvHD prophylaxis post allogeneic SCT :

-15 mg/m² on D+1 then 10 mg/m² on D+3, D+6 and D+11


Drug: Mycophenolic acid (MPA)

GvHD prophylaxis post allogeneic SCT :

  • 720 mg BID from D0 to D+28 for HLA-identical siblings
  • 720 mg BID from D0 to D+45 for 10/10 HLA allele-matched unrelated donors

Experimental: R3-MAC-MPA
Cyclosporine and mycophenolic acid
Drug: Cyclosporine

GvHD prophylaxis post allogeneic SCT :

-Cyclosporine : 3 mg/kg /day from D-1 (IV) or 6 mg/kg/day from D-3 (PO). Not to be stopped before D100


Drug: Mycophenolic acid (MPA)

GvHD prophylaxis post allogeneic SCT :

  • 720 mg BID from D0 to D+28 for HLA-identical siblings
  • 720 mg BID from D0 to D+45 for 10/10 HLA allele-matched unrelated donors

Active Comparator: R3-RIC-CICLO
Cyclosporine
Drug: Cyclosporine

GvHD prophylaxis post allogeneic SCT :

-Cyclosporine : 3 mg/kg /day from D-1 (IV) or 6 mg/kg/day from D-3 (PO). Not to be stopped before D100


Experimental: R3-RIC-MPA
Cyclosporine and mycophenolic acid
Drug: Cyclosporine

GvHD prophylaxis post allogeneic SCT :

-Cyclosporine : 3 mg/kg /day from D-1 (IV) or 6 mg/kg/day from D-3 (PO). Not to be stopped before D100


Drug: Mycophenolic acid (MPA)

GvHD prophylaxis post allogeneic SCT :

  • 720 mg BID from D0 to D+28 for HLA-identical siblings
  • 720 mg BID from D0 to D+45 for 10/10 HLA allele-matched unrelated donors

Experimental: R4-VOS-IDAC
Intermediate dose cytarabine and vosaroxin
Drug: vosaroxin

Consolidation chemotherapy course (s) :

-70 mg/m² on D1 and D4


Drug: ID cytarabine

Consolidation chemotherapy course (s) :

-Intermediate dose cytarabine: 1.5g/m² /12h on D1, D3 and D5

For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)

Up to 3 consolidation courses, depending on the patient AML risk group


Active Comparator: R4-IDAC (without VOS)
Intermediate dose cytarabine alone
Drug: ID cytarabine

Consolidation chemotherapy course (s) :

-Intermediate dose cytarabine: 1.5g/m² /12h on D1, D3 and D5

For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)

Up to 3 consolidation courses, depending on the patient AML risk group


Experimental: R4-DEX-HDAC
High dose cytarabine and dexamethasone
Drug: HD Cytarabine

Consolidation chemotherapy course (s) :

-High dose cytarabine: 3g/m² /12h on D1, D3 and D5

For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)

Up to 3 consolidation courses, depending on the patient AML risk group


Drug: Dexamethasone

Consolidation chemotherapy course (s) :

-10 mg/12h on D1, D3 and D5


Active Comparator: R4-HDAC (without DEX)
High dose cytarabine alone
Drug: HD Cytarabine

Consolidation chemotherapy course (s) :

-High dose cytarabine: 3g/m² /12h on D1, D3 and D5

For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)

Up to 3 consolidation courses, depending on the patient AML risk group


Experimental: R4-VEN-IDAC
Intermediate dose cytarabine and venetoclax
Drug: ID cytarabine

Consolidation chemotherapy course (s) :

-Intermediate dose cytarabine: 1.5g/m² /12h on D1, D3 and D5

For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)

Up to 3 consolidation courses, depending on the patient AML risk group


Drug: Venetoclax

Consolidation chemotherapy course (s) :

Once RP2D has been determined from the results of the dose selection phase (phase 1), the optimal dose level retained for randomized phase 2 will be one of the following:

  • 100 mg/d on D1 to D8 (selection phase dose level 1)
  • or 200 mg/d on D1 to D8 (selection phase dose level 2)
  • or 400 mg/d on D1 to D8 (selection phase dose level 3)
  • or 400 mg/d on D1 to D14 (selection phase dose level 4)

Active Comparator: R4-IDAC (without VEN)
Intermediate dose cytarabine alone
Drug: ID cytarabine

Consolidation chemotherapy course (s) :

-Intermediate dose cytarabine: 1.5g/m² /12h on D1, D3 and D5

For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)

Up to 3 consolidation courses, depending on the patient AML risk group





Primary Outcome Measures :
  1. Overall survival [ Time Frame: 3 years ]
    For randomizations R1 (idarubicine vs daunorubicine) and R2 (HDAC vs IDAC)

  2. Cumulative incidence (CI) of acute Graft versus Host Disease (GvHD) of grade II to IV [ Time Frame: 100 days ]
    For randomization R3 : GvHD prophylaxis study

  3. Disease free survival [ Time Frame: 18 months ]
    For randomizations R4



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 61 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria (at diagnosis) :

  1. Age ≥ 18 years and < 61 years
  2. With a newly diagnosed de novo or secondary type AML (post myelodysplastic syndrome MDS or therapy-related AML)
  3. No prior treatment for neither AML (with the exception of hydroxyurea), nor MDS (with the exception of EPO)
  4. ECOG performance status ≤ 3
  5. Absence of severe uncontrolled infection
  6. No cardiac contraindications for the use of anthracyclines : decompensated or uncontrolled heart failure, recent myocardial infarction, current signs of cardiac impairment, uncontrolled arrhythmias, LVEF (left ventricular ejection fraction) < 50%
  7. Total bilirubin ≤ 2 x upper limit of normal (UNL), ASAT(SGOT) and ALAT (SGPT) ≤ 2.5 X UNL, creatinine < 150 µmol/l, unless AML-related out of range values
  8. Genetic mutation testing of the FLT3 (FLT3-ITD ou FLT3-TKD) gene, performed in local or central laboratory
  9. Use of appropriate methods of contraception:

    • for patients treated with Midostaurin:

      • women of childbearing potential should use appropriate methods of contaception throughout treatment, and for 5 months post cessation of treatment
      • men will need to use condoms during intercourse throughout treatment, and for 5 months post cessation of treatment with Midostaurin
  10. Patients who are covered by or beneficiaries of a social security system (Social Security or Universal Medical Coverage)
  11. Patients who have read and understood the information sheet and signed the informed consent form

Exclusion criteria (at diagnosis) :

1.Patients with acute promyelocytic leukemia (APL), as confirmed either by t(15;17) or by the presence of PML-RARA fusion transcripts 2.Patients with core binding factor (CBF) AML, as confirmed either by t(8;21), t(16,16) or inv(16), or by fusion transcripts resulting from these cytogenetic abnormalities (RUNX1-RUNX1T1, CBFB-MYH11).

3.Patients with secondary AML arising from myeloproliferative disorders previously known according to the 2008 WHO classification 4.Patients with Ph1+ AML or previous Ph1+ disorder (chronic myelogenous leukemia) 5.Severe psychiatric or organic disorder, supposed to be independent from AML, that would contraindicate treatment, including allogeneic HSCT 6.No psychological, familial, social, or geographic reason that would compromise clinical follow up 7.History of uncontrolled cancer for the last 2 years, with the exception of basal cell carcinoma or carcinoma in situ of the cervix 8.Uncontrolled severe infection 9.Patients with positive serology for HIV-1 and -2, or HTLV -1 and -2, or active hepatitis virus B or C infection 10.Pregnant or lactating women 11.Legal incapacity (patients under tutorship, curatorship or judicial protection)

------------------------------------------

For randomization R4-VOS (post-induction/salvage) :

Inclusion criteria

  1. Patients enrolled in the BIG-1 trial at diagnosis
  2. Patient presenting with AML in first CR or CRp/CRi after induction or one cycle of salvage therapy (confirmed in the 15 days preceding R4-VOS)
  3. Favorable or intermediate risk AML patients, as stratified with BIG-1 prognostic classification
  4. Patients randomized to R2-IDAC arm (intermediate dose cytarabine)
  5. ECOG performance status ≤ 2
  6. Left ventricular ejection fraction (LVEF) at least 40% by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO)
  7. Local clinical laboratory values as follows:

    o Serum creatinine ≤ 2.0 mg/dL

    o Total bilirubin ≤ 1.5 X the upper limit of normal (ULN)

    • Aspartate aminotransferase (AST) ≤ 2.5 X ULN
    • Alanine aminotransferase (ALT) ≤ 2.5 X ULN
  8. Signed written informed consent for vosaroxin study (R4-VOS)
  9. Women of childbearing potential must have a negative pregnancy test within 8 days before randomization R4-VOS and commit to the use of effective contraception during the period of treatment and up to 36 days after vosaroxin has been stopped. Men must use effective contraception during the treatment period and up to 96 days after vosaroxin has been stopped.

Exclusion criteria

1.Patients classified in the unfavorable risk group according to the BIG-1 protocol classification 2.Complete remission is not attained (CR, CRp/CRi) after induction and/or salvage therapy 3.Positive pregnancy test 4.Severe uncontrolled infection such as sepsis, or multiple organ dysfunction syndrome, uncontrolled fever 5.Documented uncontrolled fungal infection (positive blood test and cultures) 6.History of myocardial infarction, unstable angina, cerebrovascular accident (CVA) or transient ischemic attack (TIA) in the 3 months before randomization 7.Patient under hemodialysis (HD) or peritoneal dialysis (PD)

------------------------------------------

For randomization R4-DEX (post-induction/salvage) :

Inclusion criteria

  1. Patients enrolled in the BIG-1 trial at diagnosis
  2. Patient presenting with AML in first CR or CRp/CRi after induction or one cycle of salvage therapy (confirmed in the 15 days preceding R4-DEX)
  3. Favorable or intermediate risk AML patients, as stratified with BIG-1 prognostic classification
  4. ECOG performance status ≤ 2
  5. Local clinical laboratory values as follows:

    • Serum creatinine ≤ 150 µmol/L
    • Total bilirubin ≤ 1.5 X the upper limit of normal (ULN)
    • Aspartate aminotransferase (AST) ≤ 2.5 X ULN
    • Alanine aminotransferase (ALT) ≤ 2.5 X ULN
  6. Signed written informed consent for dexamethasone study (R4-DEX)

Exclusion criteria

1.Severe uncontrolled infection such as sepsis, or multiple organ dysfunction syndrome, uncontrolled fever 2.Documented uncontrolled fungal infection (positive blood test and cultures 3.History of myocardial infarction, unstable angina, cerebrovascular accident (CVA) or transient ischemic attack (TIA) in the 3 months before randomization 4.Patient under hemodialysis (HD) or peritoneal dialysis (PD)

--------------------------------------

For randomization R4-VEN (post-induction/salvage) :

Inclusion criteria

  1. Age 18 - 60 years at inclusion in BIG-1 protocol
  2. diagnosis of AML according to WHO classification de novo or secondary to myelodysplastic syndrome (myelodysplastic syndrome must not have been treated except by ESA, Lenalidomide or non-chemotherapy) or therapy-related AML
  3. Patients included in the BIG-1 protocol
  4. Patients in first CR or CRp/CRi following 1 or 2 courses of induction chemotherapy according to BIG-1 protocol and who are planned to receive consolidation.
  5. Patients stratified within the favorable and intermediate risk groups as defined by BIG-1 protocol
  6. ECOG performance status ≤ 2
  7. Left ventricular ejection fraction (LVEF) at least 40% by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO)
  8. Creatinine clearance ≥ 30 ml/min (calculated by the usual method of each institution), total bilirubin ≤ 1.5 times the ULN; ASAT and ALAT ≤ times the upper limit of normal (ULN)
  9. Absence of uncontrolled infection
  10. Women of childbearing potential must agree to use effective contraception without interruption throughout the study and for a further 3 months after the end of treatment
  11. Written signed informed consent

Exclusion criteria

1.AML stratified in the unfavorable BIG-1 risk-group. 2.Diagnosis of Acute Promyelocytic Leukemia or CBF AML (ie. AML with t(8;21), t(16,16) or inv(16), or their molecular equivalents RUNX1-RUNX1T1 and CBFB-MYH11) 3.AML secondary to prior myeloproliferative disorder according to WHO classification (2008) and Philadelphia chromosome-positive AML (Ph1+) 4.Absence of CR/CRp/CRi after a maximum of two chemotherapy cycles 5.Severe medical or mental condition precluding the administration of protocol treatments 6.Prior history of cancer unless controlled for at least 2 years and except for basocellular cutaneous cancers and in situ cervix cancers 7.Positive pregnancy test 8.Breast feeding 9.Uncontrolled infection such as sepsis, or multiple organ dysfunction syndrome, uncontrolled fever 10.Documented uncontrolled fungal infection (positive blood test and cultures) 11.Prior venetoclax exposure 12.Known HBV with detectable viral load 13.Known HIV positive patients 14.Known hypersensitivity to any of the study medication 15.History of myocardial infarction, unstable angina, cerebrovascular accident (CVA) or transient ischemic attack (TIA) in the 3 months before randomization 16.Patient under hemodialysis (HD) or peritoneal dialysis (PD) 17.Concomitant treatment with cytochrome CYP3A4 inhibitor which cannot be stopped during venetoclax administration ONLY FOR PHASE 1 18.During the phase 2, for patients randomized in the IDAC + Venetoclax arm, if concomitant treatment with cytochrome CYP3A4 inhibitor cannot be stopped, a dose reduction of 70% of venetoclax must be apply

--------------------------------------

For randomization R3 (before AlloHSCT):

Inclusion criteria

  1. Patients enrolled in the BIG-1 trial at diagnosis
  2. Patient presenting with AML in first CR or CRp/CRi treated in the BIG-1 trial and classified in the intermediate risk group, namely:

    • either initially favorable but poor molecular responders for NPM1 MRD: NPM1 mutation, without FLT3-ITD mutation or with an FLT3-ITD ratio < 0.50 and MRD2 positive blood (decrease of less than 4 log from baseline at diagnosis)).
    • Or initially favorable but requiring two cycles of chemotherapy (a salvage therapy) to obtain the first CR/CRp/CRi
    • Or other immediate intermediaries
  3. No metastatic or progressive cancer, with the exception of basal cell skin carcinoma and cervical carcinoma in situ
  4. Patients with general condition preserved (ECOG ≤ 3) and with no uncontrolled severe infection
  5. Women of childbearing age must make use of effective contraception
  6. Patients who are covered by or beneficiaries of a social security system (Social Security or Universal Medical Coverage).
  7. Patients who have read and understood the information sheet and signed the informed consent form

Exclusion criteria

  1. Complete remission is not obtained (CR, CRp/CRi) after induction and/or salvage therapy
  2. Patient presenting with AML in first CR or CRp/CRi treated in the BIG-1 trial and classified either in the favorable risk group or the unfavorable risk group
  3. Patients with a severe organ or psychiatric pathology, presumed to be independent of AML and contraindicating the allograft
  4. Patients who, for family, social or geographic reasons, do not wish to be regularly monitored via consultation
  5. Uncontrolled severe infection at the time of inclusion
  6. Serology positive for HIV 1 or 2 or HTLV 1 or 2, or active HBV or HCV viral infection
  7. Pregnant women (beta-HCG positive) or currently breastfeeding
  8. Adult patient who is incapacitated, under wardship, legal guardianship, or under the protection of the courts
  9. Patients under State Medical Assistance (AME)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02416388


Contacts
Layout table for location contacts
Contact: Mathilde Hunault, PD MaHunault@chu-angers.fr
Contact: Oliver Schmidt + 33 241 356 037 oliver.schmidt@chu-angers.fr

Locations
Show Show 55 study locations
Sponsors and Collaborators
University Hospital, Angers
Layout table for additonal information
Responsible Party: University Hospital, Angers
ClinicalTrials.gov Identifier: NCT02416388    
Other Study ID Numbers: PHRC-2010-03
First Posted: April 15, 2015    Key Record Dates
Last Update Posted: October 20, 2020
Last Verified: October 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid, Acute
Leukemia, Myeloid
Leukemia
Neoplasms by Histologic Type
Neoplasms
Cytarabine
Cyclosporine
Mycophenolic Acid
Dexamethasone
Methotrexate
Daunorubicin
Venetoclax
Idarubicin
Cyclosporins
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Antimetabolites, Antineoplastic
Antimetabolites